|
|
Seryx and Signature Genetics™
|
Seryx was founded in 2002 on the initiative of American and International Scientists who realized that both physicians and patients stood to benefit from the wealth of information available from the research literature in the rapidly evolving field of Pharmacogenetics; the science which investigates the relationship between genetic variation and variation in response to drugs.
Seryx has worked diligently with experts in Pharmacogenetics to provide a focused educational report; the Signature Genetics™ Report. This report provides a summary of the relevant research findings that pertain specifically to a patient's drug regimen and genotype for key drug metabolizing enzymes. The summarized information provided in the Signature Genetics™ Report encompasses both well established results, as well as the most up-to-date peer reviewed medical research findings.
At Seryx, our dedicated team of scientists and professionals is committed to excellence in the area of comprehensive pharmacogenetic reporting.
Seryx is a privately held company and has offices in Montreal, Quebec (Canada) and Plattsburg, New York (U.S.A.) as well as Singapore.
|
|
